ORTHOCON Announces Uninterrupted Availability of HEMASORB Resorbable Hemostatic Bone Putty

IRVINGTON, N.Y., Aug. 23, 2012 /PRNewswire/ -- On August 21, 2012, the U.S. Food and Drug Administration (FDA) announced that a hemostatic bone putty has been subjected to a Class 1 recall because of potential ignition if contacted with electrosurgical cautery systems under certain conditions during surgery. ORTHOCON and its hemostatic bone putty (HEMASORB) are not associated with this recall.

For more information regarding HEMASORB, please visit www.orthocon.com or call 914.357.2612.

 

SOURCE ORTHOCON

Suggested Articles

The efficacy between Keytruda and FerGene's nadofaragene firadenovec look comparable in their studies, though Merck has at least one upper hand.

Thursday, the FDA approved the first three generic versions of Gilenya, but they may not hit the market anytime soon due to ongoing litigation.

Gilead is hoping to score a patent extension on TAF meds, but patient advocates say that would reward conduct that harmed patients.